Macrophage lipid signaling drives glioblastoma invasion and represents a therapeutic vulnerability
Study limitation reported by the research below: “The relative benefit of LPAR vs. YAP/TAZ targeting is described as context-dependent, and the specific determinants of that context are not yet defined.”